Industry’s highest density fixed array mapping catheter, covering the largest area in a fixed matrix format, can help physicians effectively map in a shorter procedure time.
The cardiovascular portfolio from Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, has launched the OPTRELL™ Mapping Catheter with TRUEref™ Technology, powered by the CARTO® 3 System, for Mapping of Complex Cardiac Arrhythmias. Industry’s highest density fixed array mapping catheter, the OPTRELL™ Mapping Catheter, is a high-density diagnostic catheter, with small electrodes arranged in a fixed array formation to provide high-definition electrophysiological mapping of complex cardiac arrhythmia cases like persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia.
Cardiac arrhythmias are a growing epidemic. AFib is the most common type of cardiac arrhythmia, impacting approximately 1.4 million people living in the UK, and nearly 40 million people worldwide.1,2 AFib is a progressive disease, and if left untreated can get worse over time or lead to other serious complications like heart disease or stroke.3,4 Catheter ablation is a safe and effective procedure to restore the heart’s incorrect electrical signals, which causes an abnormal heart rhythm.5
The OPTRELL™ Mapping Catheter includes 36 electrodes symmetrically distributed across and along six splines and combines with the CARTO® 3 System to deliver intelligent insights and high-resolution directional mapping.6 Additionally, the OPTRELL™ Mapping Catheter has tight electrode spacing and small electrodes, which produce higher signal resolution, resulting in enhanced maps of the heart.7,8 With these high-definition maps, clinicians have a better understanding of where the arrhythmia is occurring and can develop a more effective ablation strategy.
“The OPTRELL™ catheter was certainly very useful in my recent Accessory Pathway (AP) case” said Mr S Tan, consultant cardiac electrophysiologist at Mid and South Essex NHS Foundation Trust. “The clear electrograms provided by the Multipolar annotation unique to the OPTRELL™ catheter were impressively able to delineate a pathway potential that was impossible to see on bipolar signal alone due to fusion. This was confirmed on EGMs seen on the micropoles of the QDOT Micro™ ablation catheter. A single radiofrequency (RF) application here terminated AP activity within 2.6s, this seemed to lead to an overall shorter procedure time.” i
The OPTRELL™ Mapping Catheter is powered by the CARTO® 3 System, which offers Local Conduction Vectors that display the real-time direction and speed of the electrical impulses traveling through the heart.9 With these Local Conduction Vectors, clinicians gain enhanced understanding of complex circuits and mechanisms and can confidently detect gaps in ablation lesions.7 Together, these technologies can help clinicians quickly identify areas that need ablation and apply more effective therapy in a shorter time.
“The OPTRELL™ Mapping Catheter enhances the Johnson & Johnson MedTech’s cardiovascular diagnostic mapping portfolio, providing physicians with a comprehensive set of tools, integrated with our CARTO® 3 mapping system, to diagnose and treat arrhythmias.” said Polly Clements, Electrophysiology Director for Johnson & Johnson MedTech | UK & Ireland. “This latest addition to the Johnson & Johnson MedTech portfolio allows a more personalised approach to every patient in the UK, allowing all consultants with the tools to improve efficiency and effectiveness in every procedure.”
DO NOT use OPTRELL™ Mapping Catheter with TRUEref™ Technology in patients with prosthetic valves.
Footnotes
i. Mr S Tan has not been compensated for his testimonial.
References
1. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021 Feb;16(2):217-221. doi: 10.1177/1747493019897870. Epub 2020 Jan 19. Erratum in: Int J Stroke. 2020 Jan 28;:1747493020905964. PMID: 31955707.
2. NICE. Atrial Fibrillation How Common Is it? Available here. Accessed on 24 Nov 2023
3. Hugh Calkins, Gerhard Hindricks, Ricardo Cappato, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter ablation and surgical ablation of atrial fibrillation. 2017.
4. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG et al. (2016) Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. Bmj 354 i4482.
5. 5 Natale A, Reddy VY, Monir G, Wilber DJ, Lindsay BD, McElderry HT, Kantipudi C, Mansour MC, Melby DP, Packer DL, Nakagawa H. Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial. Journal of the American College of Cardiology. 2014 Aug 19;64(7):647-56.
6. 6 OPTIMUM Study, Clinical Evaluation of Arrhythmia Mapping with the Multi-Electrode OPTRELL™ Mapping Catheter. Protocol # BWI_2019_02. 28 Jan 2022.
7. Yavin H et al. Propagation Vectors Facilitate Differentiation Between Conduction Block, Slow Conduction, and Wavefront Collision. Circ Arrhythm Electrophysiol. 2021 Aug;14(8):e010081.
8. Takigawa M et al. Impact of Spacing and Orientation on the Scar Threshold With a High-Density Grid Catheter. Circ Arrhythm Electrophysiol. 2019 Sep;12(9):e007158. doi: 10.1161/CIRCEP.119.007158. Epub 2019 Aug 26. PMID: 31446771.
9. OPTRELL™ 48 Catheter Support. Instructions for Use and Release Notes. REP16038 (1.1).